Guardant Health (NASDAQ:GH) Director Sells $133,862.50 in Stock

Guardant Health, Inc. (NASDAQ:GH) Director Medina Manuel Hidalgo sold 1,250 shares of Guardant Health stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $107.09, for a total transaction of $133,862.50. Following the sale, the director owned 1,639 shares of the company’s stock, valued at $175,520.51. The trade was a 43.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Medina Manuel Hidalgo also recently made the following trade(s):

• On Friday, March 6th, Medina Manuel Hidalgo sold 1,300 shares of Guardant Health stock. The shares were sold at an average price of $91.54, for a total value of $119,002.00.

Guardant Health Price Performance

GH traded up $0.94 on Friday, reaching $118.95. 2,633,856 shares of the stock were exchanged, compared to its average volume of 2,090,416. The company’s 50-day moving average price is $90.53 and its 200 day moving average price is $98.79. Guardant Health, Inc. has a fifty-two week low of $36.36 and a fifty-two week high of $121.01. The firm has a market capitalization of $15.77 billion, a PE ratio of -35.09 and a beta of 1.48.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Thursday, February 19th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The firm had revenue of $281.27 million during the quarter, compared to analyst estimates of $269.74 million. During the same quarter in the previous year, the company earned ($0.62) earnings per share. The business’s revenue for the quarter was up 39.4% on a year-over-year basis. As a group, equities analysts forecast that Guardant Health, Inc. will post -2.92 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on GH shares. JPMorgan Chase & Co. increased their price target on shares of Guardant Health from $130.00 to $135.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Barclays lifted their price objective on shares of Guardant Health from $115.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Guggenheim increased their price objective on shares of Guardant Health from $115.00 to $135.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a report on Tuesday, April 21st. Finally, Piper Sandler set a $127.00 target price on shares of Guardant Health in a research report on Thursday. Nineteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $129.00.

Institutional Investors Weigh In On Guardant Health

Hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in shares of Guardant Health by 2.1% during the 4th quarter. Vanguard Group Inc. now owns 12,160,768 shares of the company’s stock worth $1,242,101,000 after purchasing an additional 251,939 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of Guardant Health by 33.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock valued at $575,670,000 after purchasing an additional 1,414,441 shares during the period. Baillie Gifford & Co. lifted its stake in shares of Guardant Health by 6.6% in the 3rd quarter. Baillie Gifford & Co. now owns 5,127,692 shares of the company’s stock valued at $320,378,000 after purchasing an additional 317,906 shares during the period. Franklin Resources Inc. boosted its holdings in Guardant Health by 14.9% during the fourth quarter. Franklin Resources Inc. now owns 3,361,547 shares of the company’s stock worth $343,348,000 after buying an additional 435,232 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Guardant Health by 9.4% during the fourth quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company’s stock worth $328,297,000 after buying an additional 277,001 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.